Abstract
Purpose: To investigate the therapeutic effect of baicalein on papillary thyroid cancer (PTC) cells in vitro and its underlying molecular mechanism.Methods: The human PTC cell line TPC-1 was divided into five groups and treated with distilled water or baicalein at 10, 20, 50, or 100 μM. Next, miR-206, miR-206 inhibitor, the respective negative controls of miR-206 and miR-206 inhibitor, RAP1B small interfering RNA (siRNA), and control vector siRNA were synthesized and transfected into TPC-1 cells. Cell viability, migration, and invasion were measured using the 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazolium bromide (MTT) and Transwell assays. miR-206 expression and Ras-related protein (RAP1B) levels were assessed by quantitative real-time reverse transcription-polymerase chain reaction and western blotting, respectively.Results: Baicalein inhibited TPC-1 cell viability, migration and invasion, upregulated miR-206 expression, and reduced the RAP1B level in a concentration-dependent manner (p < 0.01). miR-206 negatively regulated RAP1B expression and increased the baicalein-induced reduction of RAP1B expression. Moreover, RAP1B overexpression relieved the suppression of cell viability, migration, and invasion caused by baicalein (p < 0.01).Conclusion: Baicalein suppresses cell growth in PTC cells by regulating the miR-206/RAP1B pathway, providing a new therapeutic strategy for PTC treatment.
 Keywords: Baicalein, Papillary thyroid cancer (PTC), miR-206, RAP1B, Cell viability, Cell invasion
Highlights
Thyroid cancer is a malignant tumor that originates in the follicular epithelium of the thyroid, and it usually presents as a painless neck mass or nodule [1]
Showed that RAP1B expression is upregulated in the baicalein + miR-206 inhibitor group compared with that in the baicalein + NC inhibitor group (p < 0.01). These results suggest that baicalein can regulate miR-206 expression to increase the RAP1B expression level in TPC-1 cells
RAP1B was transfected into TPC-1 cells to assess the effect of RAP1B on papillary thyroid cancer (PTC)
Summary
Thyroid cancer is a malignant tumor that originates in the follicular epithelium of the thyroid, and it usually presents as a painless neck mass or nodule [1]. The upper membrane of the Transwell chamber was incubated in Matrigel solution (BD Biosciences, San Jose, CA, USA) for 30 min at 37°C and was co-incubated with digested TPC-1 cells for 24 h at 37°C. The Transwell assay showed that the number of migrating or invading cells in the 50μM baicalein group was less than that in the 0 μM baicalein group (Figure 1 B; p < 0.001) These data explained that baicalein could suppress PTC cell growth in vitro. Baicalein upregulates RAP1B expression by regulating miR-206 expression qRT-PCR showed that the miR-206 expression level was elevated by baicalein in a concentration-dependent manner in TPC-1 cells (Figure 2 A; p < 0.01). QRT-PCR and western blotting results both showed that RAP1B expression was increased when cells were treated with 10, 20, 50, or 100 μM baicalein (Figure 2 B and C, respectively; p < 0.01).
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
